Application of Intravenous Lidocaine in Obese Patients Undergoing Painless Colonoscopy: A Prospective, Randomized, Double-Blind, Controlled Study.

OBJECTIVE: Propofol for procedural sedation and analgesia (PSA) for colonoscopy can result in a high prevalence of severe respiratory depression. Studies have shown that intravenous (IV) infusion of lidocaine can reduce propofol requirements significantly and increase the ventilatory response to carbon dioxide in humans. We tested the hypothesis that IV lidocaine could improve propofol-induced respiratory depression in obese patients during colonoscopy.
METHODS: Ninety obese patients scheduled for painless colonoscopy were randomized to receive lidocaine (1.5 mg/kg, then 2 mg/kg/h, IV) or the same volume of 0.9% saline. Intraoperative sedation was provided by propofol. The primary outcome was the number of oxygen-desaturation episodes. Secondary outcomes were: the number of apnea episodes; total propofol consumption; time to the first hypoxia episode; time to consciousness loss; intraoperative hemodynamic parameters; awakening time; adverse events; duration of post-anesthesia care unit (PACU) stay; satisfaction of endoscopists and patients.
RESULTS: Demographic characteristics between the two groups were comparable. The number of oxygen-desaturation episodes in group L (1.49±1.12) decreased by 0.622 (P=0.018) compared with that in group N (2.11±1.32), and the number of apnea episodes in group L decreased by 0.533 (P<0.001). Kaplan-Meier curves showed that the median time to the first hypoxia episode was longer in group L (86.78 s) than that in group N (63.83 s) (Log rank P=0.0008). The total propofol consumption, awakening time, and duration of PACU stay were reduced in group L. There was no significant difference in the prevalence of adverse events (P>0.05 for all). Satisfaction scores for endoscopists and patients in group L were higher than that in group N (P<0.001).
CONCLUSION: Intravenous infusion of lidocaine could significantly reduce the number of oxygen-desaturation and apnea episodes in obese patients during painless colonoscopy. This method is worthy of clinical promotion. CLINICAL TRIALS REGISTRATION: ChiCTR2000028937.

Introduction

Many gastrointestinal-endoscopy procedures are performed under moderate or deep sedation. Propofol is the most commonly used sedative because of its shorter onset time and faster recovery than that of other anesthetics. However, hypoxemia stemming from propofol sedation continues to be the primary source of morbidity.1 As indicated in a large randomized controlled trial, the prevalence of hypoxemia in patients after intravenous (IV) injection of propofol was 20% during painless colonoscopy.2 Studies have shown that the heavier the bodyweight, the higher the prevalence of hypoxemia.3 In addition, the high prevalence of hypoxemia may be associated with mortality, myocardial ischemia, brain injury, and the risk of mechanical ventilation.4–7 Extensive researches have been carried out on propofol in combination with other drugs to lower the risk of hypoxemia. For example, dexmedetomidine has been used in combination with propofol to reduce propofol consumption.8 Unfortunately, intravenous infusion of dexmedetomidine may be accompanied by hypertension and bradycardia, which will endanger patient safety.9,10 The problem of hypoxemia induced by propofol sedation has received more attention recently, but a general agreement in clinical practice is lacking.

Lidocaine is a sodium-channel blocker and is a potential adjunct to propofol sedation. Preclinical studies have shown that IV lidocaine can reduce visceral pain in experimental animals.11 Also, lidocaine infusion with a bolus of 0–1.5 mg/kg followed by 1.5–3 mg/kg/h can significantly alleviate abdominal pain in patients.12,13 In addition, Labaille et al reported that IV lidocaine could increase the ventilatory response to carbon dioxide in humans.14 Forster and colleagues also showed that IV lidocaine could result in a 50% reduction in propofol requirements when combined with ketamine during procedural sedation and analgesia (PSA) for colonoscopy.15 However, whether IV lidocaine can reduce the number of oxygen-desaturation episodes in obese patients undergoing colonoscopy has not been investigated. We hypothesized that IV lidocaine could lower the prevalence of respiratory depression during colonoscopy in obese patients. Therefore, we undertook a prospective, double-blind, randomized controlled trial to explore the efficacy of IV lidocaine on respiratory depression in obese patients undergoing painless colonoscopy.

Materials and Methods

Ethical Approval of the Study Protocol

The study protocol was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University in Xuzhou, China. Written informed consent was obtained from all enrolled participants. The present study complies with the Declaration of Helsinki and adheres to CONSORT guidelines. Before the recruitment of the first patient, our trial was registered on 8 January 2020 on the Chinese Clinical Trial Registry (ChiCTR2000028937; main researcher: Su Liu). This study was carried out between 13 January and 31 March 2020.

Participants

Ninety obese patients (American Society of Anesthesiologists (ASA) physical status II–III; 18–75 years; body mass index (BMI) ≥30 kg/m2) scheduled to undergo painless colonoscopy in our hospital were enrolled. Then, they were allocated randomly into two groups (45 patients in each group). The exclusion criteria were patients: (i) with II- or III-degree atrioventricular block; (ii) with severe cardiac, pulmonary, hepatic or renal dysfunction; (iii) with diseases of the central nervous system or neuropsychiatric disorders; (iv) using sedative-hypnotics or analgesics for >3 months; (v) allergic to lidocaine. (vi) refusing to sign informed consent.

Randomization and Masking

Patients were allocated randomly to the lidocaine group (group L) or normal (0.9%) saline group (group N) in a 1:1 ratio by a computer-generated sequence before colonoscopy. The randomization sequence was retained in an opaque envelope by a nurse. After the patient entered the room, another anesthesiologist who was not involved in postoperative follow-up, data collection or data analyses opened the envelope and prepared the drugs according to the group allocation.

Anesthesia and Intervention

Patients who met the inclusion criteria were evaluated and screened the day before surgery. The risk of obstructive sleep apnea (OSA) was evaluated using the STOP-Bang questionnaire (comprises eight questions; total score >5 indicates a high risk of OSA; 3–4 indicates an intermediate risk of OSA; 0–2 indicates a low risk of OSA).16 Preoperative bowel preparation had been completed. An enrolled patient was excluded from the study if: he/she had a cold or fever on the day of the colonoscopy; he/she had pulse oxygen saturation (SpO2) <90% after entering the room; the duration of colonoscopy lasted 1 hour; endotracheal intubation was indicated.

All patients fasted routinely before surgery without preoperative medication. The patient entered the preparation room 15 min before the procedure. A peripheral venous channel was established on the right upper limb. Then, 250–300 mL of sodium lactate Ringer’s solution was infused before anesthesia. When the patient entered the operating room, electrocardiography, heart rate (HR), blood pressure (BP), SpO2 were monitored continuously. All patients had continuous capnographic monitoring of ventilation activity. The graphic assessment of respiratory activity was provided by the expired carbon dioxide detector attached to the nasal cannula’s tip. Oxygen (4 L/min) was supplied via a nasal cannula.

At the beginning of colonoscopy, patients were in the left lateral position. Patients in group L were administered intravenously a bolus dose of 1% lidocaine (1.5 mg/kg) before anesthesia induction. Then, 2 mg/kg of propofol was injected slowly until consciousness was lost. Propofol (4 mg/kg/h) and lidocaine (2 mg/kg/h) were infused continuously intraoperatively. Patients in group N received 0.15 mL/kg of physiologic (0.9%) saline before anesthesia induction. Then, propofol (2 mg/kg) was injected slowly until consciousness disappeared. Propofol (4 mg/kg/h) and 0.9% saline (0.4 mL/kg/h) was infused continuously intraoperatively. If necessary, propofol was titrated additionally to produce unconsciousness during anesthesia induction in two groups. Propofol dose was calculated based on the adjusted body weight (ideal body weight + 0.4 × [total body weight-ideal body weight]).17 Lidocaine dose was calculated based on the ideal body weight, according to the 2016 Enhanced Recovery After Surgery guidelines for gastrointestinal surgery.18 If a polyp or biopsy was taken and the colonoscope was returned to the ileocecum, all infusion drugs were stopped immediately. If patients expressed discomfort (involuntary movement, grimaces), an additional dose of propofol (30–40 mg) was administered. Meanwhile, the rate of propofol infusion was increased by 0.5 mg/kg/h, and repeated the process if necessary. If the patient suffered from oxygen desaturation and the interference of plethysmographic pulse waveform was excluded by the anesthesiologist, bilateral mandibles were lifted until SpO2 ≥95%, and mask ventilation was used to assist breathing if necessary. If SpO2 reverted to normal, the mask was returned to the nasal catheter for oxygen delivery. If hypotension (systolic blood pressure (SBP) <90 mmHg or descending 20% basal value) persisted for ≥1 min, phenylephrine (40 μg, IV) was administered. If bradycardia (HR <50 bpm) occurred, atropine (0.5 mg, IV) was administered. This process was repeated if necessary. Postoperatively, patients were sent to the post-anesthesia care unit (PACU) for further observation.

Outcomes

The primary outcome was the number of oxygen-desaturation episodes (defined as SpO2 <92% for ≥10 s). The main secondary outcomes were: the number of apnea episodes (defined as the absence of respiratory effort for ≥10 s, a flat line for ≥10 s shown on the capnography monitor);19 time to the first hypoxia episode (defined as time from induction to first SpO2 <92%); time to consciousness loss (defined as time from induction to the loss of eyelash reflex); total propofol consumption; the hemodynamic parameters, such as HR and SBP, at the following time points: before induction (T0); after anesthesia induction but before the procedure (T1); after endoscope insertion (T2); passing the splenic flexure of the colon (T3); passing the hepatic flexure of the colon (T4); after endoscope removal (T5). Additional secondary endpoints were: awakening time (defined as the time from the end of the procedure to patients answering their name accurately); the sedation level during PACU stay, which was scored using the Ramsay Sedation Scale (1: patients feeling anxious and agitated or restless, or both; 2: patients feeling co-operative, oriented, and tranquil; 3: patients responding to commands only; 4: patients exhibiting brisk response to light tactile stimuli or loud auditory stimulus; 5: patients exhibiting a sluggish response to light tactile stimuli or a loud auditory stimulus; 6: patients exhibiting no response). A score of 2–4 indicated “satisfactory” sedation and a score of 5–6 denoted “excessive” sedation); the pain score 1 min after awakening (evaluated by a visual analog scale (VAS) from 0 to 10; the higher the score, the more intense the pain); the prevalence of adverse events (eg, cardiac dysrhythmias, bradycardia, hypotension, nausea/vomiting, emergence agitation, hypoxia); duration of PACU stay (defined as time from the end of the procedure to discharge from the PACU); the satisfaction of endoscopists and patients (evaluated by a VAS from 0 to 10; the higher the score, the greater the satisfaction). Study outcomes were not altered after patient enrollment.

Statistical Analyses

Calculation of the sample size was undertaken by PASS 15.0 (NCSS, Kaysville, UT, USA). Based on the results of a pilot study involving 20 patients, the number of oxygen-desaturation episodes was 2.2±1.1 in group N and 1.5±1.1 in group L. With significance set at 0.05 and power set at 80%, the sample size required to detect differences was 39 patients in each group. Considering a loss to follow-up of 15%, 45 patients were required for each group.

Numeric variables were analyzed for a normal distribution by the Kolmogorov–Smirnov test. Continuous variables with a normal distribution are expressed as the mean ± standard deviation (SD) and were compared using the independent-sample t-test. Continuous variables with a non-normal distribution are expressed by the median (interquartile range) and were compared using the Mann–Whitney U-test. Categorical variables are presented as numbers (%) and were compared using the χ2 test or Fisher’s exact test. Data on hemodynamic parameters were compared by repeated-measure analysis of variance. Kaplan–Meier survival curve analysis with the Log rank test was performed to evaluate the effect of IV lidocaine on the time to first hypoxia episodes. P<0.05 was considered significant. Statistical analyses were undertaken using SPSS v24.0 (IBM, Armonk, NY, USA).

Results

A total of 106 patients were evaluated for study participation. Of these, two patients suffered from severe hypertension, one patient had been using nonsteroidal anti-inflammatory drugs for ankylosing spondylitis over 3 months and eleven patients were excluded for refusing to provide written informed consent. Finally, 92 patients were recruited in our research. After randomization, two patients were excluded; one for having a cold on the day of colonoscopy and the other for having baseline SpO2 <90% after hospitalization. Ninety patients (45 in each group) completed colonoscopy (Figure 1). The demographic characteristics between the two groups were comparable (Table 1).

Figure 1

Study population flow diagram.

Table 1

Demographic Profiles at Baseline (Randomization) in Both Groups

Variables	Group L (n=45)	Group N (n=45)	P-value
Age (years)	44.38±7.13	44.93±7.00	0.710
BMI (kg/m2)	32.08±1.72	32.24±1.48	0.627
Sex
Male	30 (67)	22 (49)	0.088
Female	15 (33)	23 (51)
ASA physical status
II	38 (84)	40 (89)	0.535
III	7 (16)	5 (11)
Hypertension	29 (64)	26 (58)	0.517
Diabetes	23 (51)	28 (62)	0.288
Mallampati score
I	2 (4)	1 (2)	0.427
II	9 (20)	7 (16)
III	24 (53)	25 (56)
IV	10 (23)	12 (26)
Perioperative Stop-Bang Score	3.96±1.02	3.96±1.18	1.000
SpO2 before Induction (%)	98.27±1.05	97.93±1.20	0.171

Notes: Data are presented as mean ± SD or numbers (%). There were no significant differences among the two groups (P>0.05). Group L= the lidocaine group; Group N= the normal saline group.

Abbreviations: BMI, body mass index; ASA, American Society of Anesthesiologists; SpO2, pulse oxygen saturation.

The number of oxygen-desaturation episodes in group L (1.49±1.12) decreased by 0.622 (95% confidence interval (CI), −1.135 to −0.110, P=0.018) compared with that in group N (2.11±1.32). Compared with group N (2.16±0.37), the number of apnea episodes in group L (1.62±0.49) decreased by 0.533 (95% CI, −0.715 to −0.352, P<0.001) (Table 2). The intraoperative SBP in group L was lower than that in group N (Figure 2), whereas the HR in group L was more stable than that in group N.

Table 2

Comparisons of Intraoperative Outcomes in Both Groups

Variables	Group L (n=45)	Group N (n=45)	P-value
Operation duration (min)	21.65±3.23	22.95±4.84	0.136
Total 2% lidocaine consumption (mg)	139.89±4.99	/	/
Total propofol consumption (mg)	276.49±23.30	310.73±30.20	<0.001
The number of hypoxemia episodes	1.49±1.12	2.11±1.32	0.018
The number of apnea episodes	1.62±0.49	2.16±0.37	<0.001
Time to consciousness loss (s)	26.72±7.59	36.30±4.15	<0.001
Intraoperative bradycardia	10 (22)	9 (20)	0.796
Intraoperative hypotension	4 (9)	3 (7)	0.694

Notes: Data are presented as mean ± SD or numbers (%). Group L= the lidocaine group; Group N= the normal saline group.

Abbreviations: VAS, visual analogue score; PACU, post-anesthesia care unit.

Figure 2

Intraoperative hemodynamic parameters in both groups.

Notes: Group L= the lidocaine group; Group N= The normal saline group. T0= Before induction; T1= After anesthesia induction but before the procedure; T2= After endoscope insertion; T3= Passing the splenic flexure of the colon; T4= Passing the hepatic flexure of the colon; T5= After endoscope removal. * P<0.05 Group N vs Group L.

Abbreviations: SBP, systolic blood pressure; HR, heart rate.

The Kaplan–Meier curve showed that the median time to the first hypoxia episode was longer in group L (86.78 s) than that in group N (63.83 s) (hazard ratio = 0.430, 95% CI, 0.263 to 0.703), and the Log rank test showed that this difference was significant (P=0.0008) (Figure 3). Compared with group N (310.73±30.21 mg), the total propofol consumption in group L (276.49±23.30 mg) was reduced by 34 mg (95% CI, −45.55 to −22.94, P<0.001).

Figure 3

Kaplan–Meier curves for time to first hypoxia episodes.

Notes: Group L= the lidocaine group; Group N= the normal saline group.

The Ramsay score was lower in group L (2.84±0.56) than that in group N (3.27±0.58) (P=0.01). The 1-min VAS score after colonoscopy was lower in group L (2.11±0.32) than that in group N (2.80±0.59) (P<0.001). Compared with group N, group L did not show a significant difference in the prevalence of bradycardia, hypotension, nausea/vomiting, or use of atropine and phenylephrine (P>0.05 for all). The satisfaction score for endoscopists and patients in group L was greater than that in group N (P<0.001) (Table 3). No cardiac dysrhythmias were detected during the colonoscopy, and no patients had symptoms of toxicity after awakening (eg, dizziness, drowsiness, oral metal odor, mouth paresthesia, blurred vision).

Table 3

Comparisons of Postoperative Outcomes During PACU in Both Groups

Variables	Group L (n=45)	Group N (n=45)	P-value
Awakening time (min)	8.27±1.30	12.2±1.95	<0.001
Bradycardia	5 (11)	7 (16)	0.535
Hypotension	3 (7)	5 (11)	0.459
Nausea/Vomiting	11 (24)	12 (27)	1.000
Emergence agitation	6 (13)	15 (33)	0.025
Hypoxia	1 (2)	2 (4)	0.557
Ramsay Score	2.84±0.56	3.27±0.58	0.001
1min VAS after awakening	2.11±0.32	2.80±0.59	<0.001
Duration of PACU stay	14.96±2.21	22.56±3.40	<0.001
Endoscopists’ satisfaction	8.78±0.70	8.00±0.00	<0.001
Patients’ satisfaction	8.96±0.37	8.27±0.62	<0.001

Notes: Data are presented as mean ± SD or numbers (%). Group L= the lidocaine group; Group N= the normal saline group.

Abbreviations: VAS, visual analogue score; PACU, post-anesthesia care unit.

Discussion

We demonstrated that IV lidocaine during painless colonoscopy in obese patients could reduce the number of oxygen-desaturation and apnea episodes, decrease the total propofol consumption, as well as shorten the duration of consciousness loss, awakening time, and PACU stay compared with propofol for sedation. IV lidocaine could also relieve pain, avoid excessive sedation during recovery, and improve the satisfaction score of endoscopists and patients. Moreover, there were no lidocaine-related adverse reactions.

The popularity of painless endoscopy has relieved the discomfort caused by mechanical stimulation in conventional colonoscopy. Propofol has been the first choice of sedative drug for painless colonoscopy because of its rapid onset of action, strong sedation, short half-life, rapid recovery, and lack of drug accumulation.20,21 However, during the induction and maintenance of anesthesia, after intravenous injection of propofol, the blood concentration of propofol increases rapidly, which often results in respiratory depression and low blood pressure.22 Furthermore, due to the physiologic changes of the airways that fat infiltration of the upper airway and its surrounding structures,23 obese patients are prone to predisposing upper airway narrowing. Also, the volume of distribution of propofol is increased in obese patients for its lipid-soluble characteristics, usually resulting in a higher dose to reach the sedation level and prolonged elimination.24 Obese patients have a high prevalence of respiratory depression with propofol for sedation. In severe cases, oxygen desaturation caused by propofol sedation even threatens the safety of patients.25 Therefore, it is of crucial clinical value to prevent hypoxemia during painless colonoscopy in obese patients.

There was no significant difference in preoperative BMI or STOP-Bang scores of obese patients between the two groups, which suggests that the risk of suffering respiratory depression in both groups was similar. With reference to previous studies,19,26 oxygen desaturation in our study was defined as SpO2 <92% for ≥10 sec, and apnea was defined as an absence of respiratory effort ≥10 sec. We defined hypoxemia for SpO2<92% for ≥10 s to exclude the interference of the plethysmographic pulse waveform. To avoid the damage caused by prolonged hypoxemia to patients, the observation time was defined as 10 sec instead of a long time.27 Compared with group N, the number of oxygen-desaturation episodes and apnea in group L was reduced significantly, and the Kaplan–Meier curve showed that the median time to the first hypoxia episode was increased by about one-third in group L compared with that in group N. Hence, IV lidocaine could improve respiratory depression in obese patients during painless colonoscopy. A possible explanation for this observation might be that, after intravenous administration of lidocaine, the requirement for propofol in obese patients during painless colonoscopy was decreased significantly. Propofol is associated with a higher risk of respiratory depression in a dose-dependent manner.28 Hence, the respiratory inhibition caused by propofol was also alleviated significantly. These findings reported by Hans and colleagues suggest that these propofol-sparing effects of IV lidocaine are not mediated by a pure hypnotic effect but rather by anti-nociceptive action, and lidocaine does not affect propofol requirements in the absence of surgical stimulation.29 In the study by Altermatt et al, the findings also demonstrate that IV lidocaine can reduce propofol requirements during surgical stimulation and further confirm that the propofol-sparing effects of IV lidocaine are not related to pharmacokinetic interactions between propofol and lidocaine.30 Another possible explanation for this finding is that lidocaine does not cause respiratory inhibition and dilates bronchial smooth muscle,31–33 thereby preventing airway reactivity on emergence in obese patients. Additionally, IV lidocaine could induce a stimulation of the ventilatory response to carbon dioxide.14 Besides the relief of respiratory depression, in group L, the duration of consciousness recovery and duration of PACU stay was shortened by 30%, and the degree of sedation during recovery time was reduced. Therefore, perioperative administration of lidocaine could avoid the over-sedation effect caused by an excessive dose of propofol.

Abdominal pain is a common complication of colonoscopy. It is associated with the swelling of the intestinal cavity caused by water and gas injection or mechanical stretching of the intestinal wall caused by the enteroscope during colonoscopy.34 The 1-min VAS score during the recovery time in group L was lower than that in group N, which suggests that IV lidocaine produced an analgesic effect. A meta-analysis35 involving 354 patients conducted by Li and colleagues found that intravenous infusion of lidocaine (1.5 mg/kg/h) inhibited pain after cholecystectomy. Koppert et al36 showed that the analgesic effect of IV lidocaine could be extended to 72 h after surgery.

Lidocaine is an amide-type local anesthetic. It represses the generation and conduction of action potentials in nerves through inhibition of sodium channels, thereby exerting an analgesic effect at central and peripheral levels.37,38 In addition, several studies have shown that IV lidocaine can reduce the release of pro-inflammatory cytokines, alleviate inflammatory pain, and accelerate the recovery of intestinal function.39,40 Studies have demonstrated that lidocaine can also block the neurotransmission of damaged nervous tissue, inhibit migration of granulocytes and lysosomes, and reduce production of pro-inflammatory and anti-inflammatory cytokines, thereby exerting an anti-hyperalgesic effect.41,42

Although the propofol dose in group L was reduced, the duration of colonoscopy was not prolonged compared with that in group N. This phenomenon did not lower the satisfaction score of endoscopists, suggesting that the reduction of sedative drugs did not affect the endoscopists’ procedure. These results are in agreement with those obtained by Forster and colleagues.15 We found that, during colonoscopy, the intraoperative HR and SBP in group L were lower than those in group N. This difference can be explained (at least in part) by the analgesic effect provided by lidocaine. Bradycardia and hypotension are common adverse reactions of propofol. However, there was no significant difference between the two groups in the prevalence of bradycardia or hypotension intraoperatively. The reason may be that the sample size was insufficient to reflect the difference between the two groups because the sample calculation was based on the number of hypoxemia episodes.

For patients undergoing continuous intravenous administration of lidocaine during colonoscopy, the main concern was whether the total dose of lidocaine exceeded the safe upper limit that causes neurologic or cardiovascular toxicity. To answer this question, we designed the experiment very carefully. First, in terms of determination of the concentration and dose of lidocaine, we strictly followed the 2016 Enhanced Recovery After Surgery guidelines for gastrointestinal surgery.18 It was recommended that lidocaine be injected intravenously at 1.5 mg/kg within 30 min before anesthesia induction (based on the ideal body weight) and then infused continuously at 2 mg/kg/h (based on the ideal body weight) during the procedure for multimodal analgesia. Second, studies have shown that the safe upper limit of lidocaine concentration in plasma was 5 μg/mL, which indicated that a plasma concentration >5 μg/mL was associated with neurologic symptoms.43,44 In the study conducted by Carabalona et al,45 42 obese patients undergoing laparoscopic bariatric surgery were given an IV bolus of lidocaine 1.5 mg/kg followed by a continuous infusion of 2.0 mg/kg/h until the end of the surgery. The median serum concentration was 1.45 (0.98–1.88) μg/mL and no serum concentrations of lidocaine exceeded 5 μg/mL, which indicates that it is safe to administer intravenously at this infusion rate in obese patients. Compared with non-obese patients, the elimination half-life of lidocaine in obese patients was markedly prolonged,46 primarily due to the increase in the absolute volume of distribution induced by higher body weight.47 However, there are rare clinical reports of adverse effects of prolonged elimination half-life in obese patients. In addition, all patients in group L were observed closely during the perioperative period, and none of them showed cardiovascular toxicity (eg, increasing intervals, widening QRS complex) or any symptoms of toxicity (eg, dizziness, drowsiness, oral metal odor, mouth paresthesia, blurred vision). Based on previous studies48,49 and the clinical signs of patients in our trial, the plasma concentration of lidocaine achieved at this infusion rate was less than the toxic concentration, which is within the safe range of medication.

There were also a few limitations in our study. First, we did not measure the plasma concentration of lidocaine after lidocaine administration. The safety of IV lidocaine was estimated through clinical manifestations of patients. None of the patients showed any signs of local anesthetic intoxication in our study. To a certain extent, it can be considered that the no serum concentration of lidocaine exceeded the non-toxic range. However, the altered physiology of obesity may increase the disposition or alter the clearance of lidocaine, thereby prolonging the elimination half-life. Therefore, future studies should be performed in terms of pharmacokinetics in obese patients to confirm the safety of IV lidocaine for colonoscopy. Second, we did not set a lean control group. However, other studies have shown that IV lidocaine in non-obese patients could result in a remarked reduction of propofol during colonoscopy.15,50 There are no lidocaine-related adverse reactions in patients undergoing bariatric surgery.49 However, we will further explore the efficacy of intravenous lidocaine in non-obese patients. Third, we did not compare lidocaine with opioids in combination with propofol for procedural sedation and analgesia. Other studies have confirmed the opioid-sparing effect of lidocaine in laparoscopic surgeries.32,51 Further studies should be conducted to explore the efficacy of IV lidocaine for procedural sedation and analgesia to decrease opioid consumption and opioid-related complications including respiratory depression. Finally, the recovery of the intestinal function after colonoscopy did not receive attention in our study for the reason that patients discharged from the PACU immediately after recovery, further trials should be confirmed.

Conclusions

Intravenous infusion of lidocaine could significantly decrease the number of oxygen-desaturation and apnea episodes in obese patients during colonoscopy. This method is worthy of clinical promotion.